INVIVO-mAb Anti CTLA4
Melanoma (Animal)
Key Facts
About SYTE.bio
SYTE.bio is a private, clinical-stage biotech leveraging synthetic biology to create non-viral DNA and RNA therapeutics and vaccines for human and animal health. The company has advanced its lead animal oncology program, INVIVO-mAb Anti CTLA4, into Phase III trials, demonstrating progress in its pipeline. With a dual-platform technology strategy and a focus on safety and efficacy, SYTE.bio aims to address unmet needs in areas like oncology, chronic diseases, and infectious diseases. The company operates with a global footprint, including offices in Boston and Buenos Aires.
View full company profileAbout SYTE.bio
SYTE.bio is a private, clinical-stage biotech leveraging synthetic biology to create non-viral DNA and RNA therapeutics and vaccines for human and animal health. The company has advanced its lead animal oncology program, INVIVO-mAb Anti CTLA4, into Phase III trials, demonstrating progress in its pipeline. With a dual-platform technology strategy and a focus on safety and efficacy, SYTE.bio aims to address unmet needs in areas like oncology, chronic diseases, and infectious diseases. The company operates with a global footprint, including offices in Boston and Buenos Aires.
View full company profileAbout SYTE.bio
SYTE.bio is a private, clinical-stage biotech leveraging synthetic biology to create non-viral DNA and RNA therapeutics and vaccines for human and animal health. The company has advanced its lead animal oncology program, INVIVO-mAb Anti CTLA4, into Phase III trials, demonstrating progress in its pipeline. With a dual-platform technology strategy and a focus on safety and efficacy, SYTE.bio aims to address unmet needs in areas like oncology, chronic diseases, and infectious diseases. The company operates with a global footprint, including offices in Boston and Buenos Aires.
View full company profileAbout SYTE.bio
SYTE.bio is a private, clinical-stage biotech leveraging synthetic biology to create non-viral DNA and RNA therapeutics and vaccines for human and animal health. The company has advanced its lead animal oncology program, INVIVO-mAb Anti CTLA4, into Phase III trials, demonstrating progress in its pipeline. With a dual-platform technology strategy and a focus on safety and efficacy, SYTE.bio aims to address unmet needs in areas like oncology, chronic diseases, and infectious diseases. The company operates with a global footprint, including offices in Boston and Buenos Aires.
View full company profile